Whether Detection of Gene Mutations Could Identify Low- or High-Risk Papillary Thyroid Microcarcinoma? Data from 393 Cases Using the Next-Generation Sequencing
Table 4
Patient characteristics and genetic alterations of cN0 PTCs (n = 300).
Total
≤5 mm
n = 300
n = 103
n = 151
n = 46
Gender
M
83 (27.7%)
25 (24.3%)
39 (25.8%)
19 (41.3%)
0.077
F
217 (72.3%)
78 (75.7%)
112 (74.2%)
27 (58.7%)
Age at diagnosis (years)
43.9 ± 12.0
44.8 ± 10.9
43.8 ± 12.6
41.9 ± 12.2
0.406
Maximum tumor size (mm)
Mean ± SD
7.3 ± 3.2
3.9 ± 1.1
7.9 ± 1.5
12.7 ± 1.3
<0.001
Chronic lymphocytic thyroiditis
Yes
47 (15.7%)
15 (14.6%)
24 (15.9%)
8 (17.4%)
0.903
No
253 (84.3%)
88 (85.4%)
127 (84.1%)
38 (82.6%)
Bilateralism
Yes
50 (16.7%)
13 (12.6%)
23 (15.2%)
14 (30.4%)
0.061
No
250 (83.3%)
90 (87.4%)
128 (84.8%)
32 (69.6%)
Multifocality
Yes
105 (35.0%)
30 (29.1%)
53 (35.1%)
22 (47.8%)
0.087
No
195 (65.0%)
73 (70.9%)
98 (64.9%)
24 (52.2%)
Intrathyroid spread
Yes
6 (2.0%)
1 (1.0%)
2 (1.3%)
3 (6.5%)
0.088
No
294 (98.0%)
102 (99.0%)
149 (98.7%)
43 (93.5%)
Extrathyroidal extension
Yes
35 (11.7%)
8 (7.8%)
21 (13.9%)
6 (13.0%)
0.310
No
265 (88.3%)
95 (92.2%)
130 (86.1%)
40 (87.0%)
Lymph node metastases
No
161 (53.7%)
76 (73.8%)
71 (47.0%)
14 (30.4%)
<0.001
Yes (central compartment)
139 (46.3%)
27 (26.2%)
80 (53.0%)
32 (69.6%)
>5
34 (11.3%)
1 (1.0%)
23 (15.2%)
10 (21.7%)
<0.001
≤5
266 (88.7%)
102 (99.0%)
128 (84.8%)
36 (78.3%)
Staging (VIII ed. TNM)
I
277 (92.3%)
97 (94.2%)
138 (91.4%)
42 (91.3%)
0.699
II
23 (7.7%)
6 (5.8%)
13 (8.6%)
4 (8.7%)
Tumor recurrence
Yes
5 (1.7%)
1 (1.0%)
2 (1.3%)
2 (4.3%)
0.299
No
293 (97.7%)
102 (99.0%)
148 (98.0%)
43 (93.5%)
0.135
n.a.
2 (0.6%)
0 (0%)
1 (0.7%)
1 (2.2%)
0.401
BRAFV600E mutation
Yes
252 (84.0%)
71 (68.9%)
137 (90.7%)
44 (95.7%)
<0.001
No
48 (16.0%)
32 (31.1%)
14 (9.3%)
2 (4.3%)
KRAS mutation
wt.
299 (99.7%)
102 (99.0%)
151 (100%)
46 (100%)
0.497
Q61K
1 (0.3%)
1 (1.0%)
0 (0%)
0 (0%)
NRAS mutation
wt.
298 (99.3%)
103 (100%)
150 (99.3%)
45 (97.8%)
0.401
Q61R
2 (0.7%)
0 (0%)
1 (0.7%)
1 (2.2%)
RET/PTC
wt.
294 (98.0%)
101 (98.0%)
148 (98.0%)
45 (97.8%)
1.000
RET/PTC1
5 (1.7%)
1 (1.0%)
3 (2.0%)
1 (2.2%)
0.709
RET/PTC3
1 (0.3%)
1 (1.0%)
0 (0%)
0 (0%)
0.497
wt: wild type, na: not available, and PTC: papillary thyroid carcinoma. Data are expressed as mean ± SD or absolute number (%). value means statistical analysis among the three groups by ANOVA or chi-square test. Data are expressed as mean ± SD or absolute number (%). Significant differences are shown in bold characters .
